<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158138">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01988493</url>
  </required_header>
  <id_info>
    <org_study_id>200095-004</org_study_id>
    <nct_id>NCT01988493</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Subjects With Hepatocellular Carcinoma</brief_title>
  <official_title>A Multicenter, Randomized, Phase Ib/II Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of MSC2156119J as Monotherapy Versus Sorafenib in Asian Subjects With MET+ Advanced Hepatocellular Carcinoma and Child-Pugh Class A Liver Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <authority>Taiwan : Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, integrated, Phase 1b/2 trial to determine the recommended Phase 2
      dose (RP2D) and to evaluate the efficacy, safety, and pharmacokinetic of MSC2156119J as
      first-line treatment versus sorafenib in subjects with MET+, Barcelona Clinic Liver Cancer
      (BCLC) Stage C, systemic treatment naive advanced hepatocellular carcinoma (HCC) and
      Child-Pugh class A liver function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Subjects Experiencing Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Up to Day 21 of Cycle 1</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Adverse Events (AEs)</measure>
    <time_frame>Baseline up to Day 30 after the last dose of study treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Progression (TTP) Assessed by an Independent Review Committee (IRC)</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>TTP assessed by an IRC will be measured from randomization until disease progression or study drug discontinuation assessed every 2 cycles up to Cycle 13, and thereafter every 4 cycles up to 2 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) Time</measure>
    <time_frame>Time from randomization to disease progression or occurrence of death due to any cause within 42 days of either randomization or the last tumor assessment up to 12 months after last subject's first dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Time</measure>
    <time_frame>Time from randomization to the date of death or up to 2 years whichever occur first</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall survival time will be measured from randomization to the date of death or up to 2 years whichever occur first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTP Assessed by Investigator</measure>
    <time_frame>Time from randomization until disease progression or study drug discontinuation assessed every 2 cycles up to Cycle 13, and thereafter every 4 cycles up to 12 months after last subject's first dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-Symptomatic Progression (TTSP)</measure>
    <time_frame>Time from randomization up to Day 30 after the last dose of study treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameters: AUC (0-t), AUC (0-tau), AUC (0-infinity), Cmax, Cav, Cmin, tmax, CL/f, Vz/f, Vss/f, lambda_z and t1/2</measure>
    <time_frame>Days 1 and 15 of Cycle 1 and Day 1 of Cycle 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with Objective Response (OR)</measure>
    <time_frame>Time from randomization until disease progression or study drug discontinuation assessed every 2 cycles up to Cycle 13, and thereafter every 4 cycles up to 12 months after last subject's first dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with disease control according to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) criteria</measure>
    <time_frame>Time from randomization until disease progression or study drug discontinuation assessed every 2 cycles up to Cycle 13, and thereafter every 4 cycles up to 12 months after last subject's first dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Disease control is defined as proportion of subjects with complete response (CR), partial response (PR), or stable disease (SD) as the best overall response according to RECIST v1.1.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>MSC2156119J</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSC2156119J</intervention_name>
    <description>MSC2156119J will be administered at a total dose range of 300-500 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or subject withdrawal. Dose adjustment will be done as per investigator's discretion based upon individual subject's tolerability.</description>
    <arm_group_label>MSC2156119J</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib will be administered at a dose of 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or subject withdrawal. Dose adjustment will be as per investigator's discretion based upon clinical circumstance, taking references to the description in the package insert.</description>
    <arm_group_label>Sorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed HCC

          -  Subjects with advanced HCC of BCLC Stage C

          -  A tumor biopsy is required for determining MET status

          -  MET+ status (Phase 2 only), as determined by the central laboratory (phase 1b
             retrospectively, Phase 2 for subject selection) as defined in the protocol

          -  Child-Pugh class A with no encephalopathy according to the screening assessment

          -  Asian male or female, 18 years of age or older

          -  Measurable disease in accordance with RECIST v1.1 (Phase 2 only)

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2

          -  Eligible for treatment with sorafenib, as assessed by investigators according to the
             Package Insert and clinical judgment (Phase 2 only)

          -  Signed and dated informed consent indicating that the subject has been informed of
             all the pertinent aspects of the trial prior to enrollment

          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests, and other trial procedures

          -  Life expectancy judged by the investigator of at least 3 months

        Exclusion Criteria:

          -  Prior systemic anticancer treatment for advanced HCC, including targeted therapy (for
             example, sorafenib), chemotherapy, or any other investigational agent (Phase 2 only)

          -  Prior treatment with any agent targeting the hepatocyte growth factor (HGF)/c-Met
             pathway

          -  Prior local-regional therapy within 4 weeks prior to Day 1 of trial treatment

          -  Prior history of liver transplant

          -  Laboratory index at baseline as defined in the protocol

          -  Past or current history of neoplasm other than HCC, except for curatively treated
             non-melanoma skin cancer, in situ carcinoma of the cervix, or other cancer curatively
             treated and with no evidence of disease for at least 5 years

          -  Known central nervous system (CNS) or brain metastasis that is either symptomatic or
             untreated

          -  Medical history of difficulty swallowing, malabsorption, or other chronic
             gastrointestinal disease, or conditions that may hamper compliance and/or absorption
             of the tested products

          -  Clinically significant gastrointestinal bleeding within 4 weeks before trial entry

          -  Peripheral neuropathy Grade greater than or equal to 2 (Common Terminology Criteria
             for Adverse Events [CTCAE] v4.0)

          -  Impaired cardiac function as defined in the protocol

          -  Hypertension uncontrolled by standard therapies

          -  Subject with a family history of long QT syndrome or who take any agent that is known
             to prolong QT/QTc interval

          -  Known human immunodeficiency virus (HIV) infection

          -  Known or suspected drug hypersensitivity to any ingredients of sorafenib (Phase 2
             only) and MSC2156119J

          -  Female subjects who are pregnant or lactating, or males and females of reproductive
             potential not willing or not able to employ a highly effective method of birth
             control/contraception to prevent pregnancy from 2 weeks before receiving study drug
             until 3 months after receiving the last dose of  study drug

          -  Concurrent treatment with a non-permitted drug

          -  Substance abuse, other acute or chronic medical or psychiatric condition, or
             laboratory abnormalities that may increase the risk associated with trial
             participation in the opinion of the investigator

          -  Participation in another clinical trial within the past 28 days

          -  Previous anticancer treatment-related toxicities not recovered to baseline or Grade
             0-1 (except alopecia and peripheral neuropathy)

          -  Subjects with any concurrent medical condition or disease that will potentially
             compromise the conduction of the study at the discretion of the investigators
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Merck KGaA Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@merckgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Please contact the Merck KGaA Communication Center</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 6151 72 5200</phone>
      <email>service@merckgroup.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 14, 2014</lastchanged_date>
  <firstreceived_date>November 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinoma, Hepatocellular</keyword>
  <keyword>MSC2156119J</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Recommended Phase 2 dose</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
